Learn From Our Experts Presenting At The 2026 VEITHsymposium

Don't miss new information on drug-coated balloons and drug-eluting stents for femoral-popliteal arterial occlusive lesions: Updates on randomized controlled trials and other exciting clinical findings.

Konstantinos Katsanos, MSc, MD, PhD, EBIR

Although Paclitaxel Coated Devices Confer No Increase In Mortality Rates, They Still May Increase Amputation Rates When Used To Treat CLTI Patients: What Mechanism May Be Responsible

Higher Amputation Rates From Paclitaxel Coated Devices May Be A Methodological Artifact But May Be Real: Paclitaxel Coating Has Other Bad Effects (Embolization Or Post Atherectomy Aneurysm): The SWEDEPAD 2 Study Showed No Paclitaxel Benefit And Possibly Increased Mortality: So When Should Paclitaxel Coated Devices Be Used And When Not

Peter A. Schneider, MD

Fabrizio Fanelli, MD, EBIR

Comparative Long-Term Outcomes With DESs And DCBs To Treat Fem-Pop Lesions: Unique Observations After 2-12 Years In 1000 Patients: What Is The Best Technique For Vessel Preparation

Treatment Of Fem-Pop Lesions With DCBs vs. DESs: Findings From A 3-Year Propensity Score-Matched Analysis: Which Device Is Best And When: A Novel Method For Preventing Distal Emboli During Endovascular Treatments: The Flow-Controlled Anti-Embolic Technique

Osamu Iida, MD, PhD

Yann Gouëffic, MD, PhD

Systematic Review And Meta-Analysis Of Fem-Pop Endovascular Treatments With DESs, DCBs, Covered Stents And Bare Metal Stents (BMSs): When Is Each Best And Which Gives The Best Quality Of Life: What Is The Hard Evidence

Comparative Long-Term Performance Of Zilver PTX (Cook) And Eluvia (Boston Scientific) DESs For Fem-Pop Disease: Both Are Effective: Advantages And Limitations Of Each Regarding Cost And Need For Redo Procedures

Charles J. Bailey, MD

Gunnar Tepe, MD

Three-Year Results Of The SPORTS RCT – Comparing DESs (Eluvia – Boston Scientific) vs. DCBs And BMSs: Which Treatment Is Best And In What Circumstances: Why Do DCBs Fail In TASC C And D Lesions

Long-Term Results Of An RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating Fem-Pop Lesions: From The TRANSCEND Trial: How Do The Two Devices Differ

Peter Schneider, MD

Brian G. DeRubertis, MD

Directional Atherectomy As Vessel Prep For DCB Use For Fem-Pop Lesions: For Which Lesion Characteristics Is It The Best Treatment: What Is The Evidence For Its Superiority

Learn From Our Experts Presenting At The 2026 VEITHsymposium

Although Paclitaxel Coated Devices Confer No Increase In Mortality Rates, They Still May Increase Amputation Rates When Used To Treat CLTI Patients: What Mechanism May Be Responsible

Comparative Long-Term Outcomes With DESs And DCBs To Treat Fem-Pop Lesions: Unique Observations After 2-12 Years In 1000 Patients: What Is The Best Technique For Vessel Preparation

Treatment Of Fem-Pop Lesions With DCBs vs. DESs: Findings From A 3-Year Propensity Score-Matched Analysis: Which Device Is Best And When: A Novel Method For Preventing Distal Emboli During Endovascular Treatments: The Flow-Controlled Anti-Embolic Technique

﻿Systematic Review And Meta-Analysis Of Fem-Pop Endovascular Treatments With DESs, DCBs, Covered Stents And Bare Metal Stents (BMSs): When Is Each Best And Which Gives The Best Quality Of Life: What Is The Hard Evidence

Comparative Long-Term Performance Of Zilver PTX (Cook) And Eluvia (Boston Scientific) DESs For Fem-Pop Disease: Both Are Effective: Advantages And Limitations Of Each Regarding Cost And Need For Redo Procedures

﻿Three-Year Results Of The SPORTS RCT – Comparing DESs (Eluvia – Boston Scientific) vs. DCBs And BMSs: Which Treatment Is Best And In What Circumstances: Why Do DCBs Fail In TASC C And D Lesions

﻿Long-Term Results Of An RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating Fem-Pop Lesions: From The TRANSCEND Trial: How Do The Two Devices Differ

﻿Directional Atherectomy As Vessel Prep For DCB Use For Fem-Pop Lesions: For Which Lesion Characteristics Is It The Best Treatment: What Is The Evidence For Its Superiority

Systematic Review And Meta-Analysis Of Fem-Pop Endovascular Treatments With DESs, DCBs, Covered Stents And Bare Metal Stents (BMSs): When Is Each Best And Which Gives The Best Quality Of Life: What Is The Hard Evidence

Three-Year Results Of The SPORTS RCT – Comparing DESs (Eluvia – Boston Scientific) vs. DCBs And BMSs: Which Treatment Is Best And In What Circumstances: Why Do DCBs Fail In TASC C And D Lesions

Long-Term Results Of An RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating Fem-Pop Lesions: From The TRANSCEND Trial: How Do The Two Devices Differ

Directional Atherectomy As Vessel Prep For DCB Use For Fem-Pop Lesions: For Which Lesion Characteristics Is It The Best Treatment: What Is The Evidence For Its Superiority